Tai PK, Albers MW, McDonnell DP, Chang H, Schreiber SL, Faber LE. Potentiation of progesterone receptor-mediated transcription by the immunosuppressant FK506. Biochemistry. 1994;33(35):10666-71.

Izar B, Sharfman W, Hodi S, et al. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Med. 2017;6(8):1904-1914. doi:10.1002/cam4.1140.

Balan S, Arnold-Schrauf C, Abbas A, et al. Large-Scale Human Dendritic Cell Differentiation Revealing Notch-Dependent Lineage Bifurcation and Heterogeneity. Cell Rep. 2018;24(7):1902-1915.e6. doi:10.1016/j.celrep.2018.07.033.

Serra V, Eichhorn PJA, García-García C, et al. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. J Clin Invest. 2013;123(6):2551-63. doi:10.1172/JCI66343.

Wang J, Mikse O, Liao RG, et al. Ligand-associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3-dependent cancer cells. Oncogene. 2015;34(17):2167-77. doi:10.1038/onc.2014.161.

Chen G, McQuade JL, Panka DJ, et al. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016;2(8):1056-64. doi:10.1001/jamaoncol.2016.0509.

Wang X, Imber BS, Schreiber SL. Small-molecule reagents for cellular pull-down experiments. Bioconjug Chem. 2008;19(3):585-7. doi:10.1021/bc700297j.